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Abstract: Routine diagnostic magnetic resonance imaging (MRI) utilises 
enhancement of the tumour tissue as a marker of malignancy in 
intracranial gliomas. However, several high-grade tumours do not exhibit 
enhancement and conversely, some low-grade gliomas do demonstrate 
enhancement. Hence, conventional MRI has a limited role in the accurate 
grading of gliomas. Advanced MRI methods that evaluate the tissue 
microstructure and tumour haemodynamics provide a better understanding of 
tumour biology and promise to provide more accurate grading. These 
advanced MRI methods include diffusion-weighted imaging (DWI), diffusion 
tensor imaging (DTI), diffusion-kurtosis imaging (DKI), arterial spin 
labelling (ASL) imaging, dynamic-susceptibility contrast (DSC) imaging 
and dynamic contrast-enhanced (DCE) imaging. This review focuses on the 
utility of these methods for better characterisation and grading of non-
enhancing gliomas and discusses how quantitative MRI data can be utilized 
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Abstract: 
Routine diagnostic magnetic resonance imaging (MRI) utilises enhancement of the tumour tissue as a 
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tumour biology and promise to provide more accurate grading. These advanced MRI methods include 
diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI), diffusion-kurtosis imaging 
(DKI), arterial spin labelling (ASL) imaging, dynamic-susceptibility contrast (DSC) imaging and  
dynamic contrast-enhanced (DCE) imaging. This review focuses on the utility of these methods for 
better characterisation and grading of non-enhancing gliomas, as it is more difficult to accurately 












*Disclosure-Conflict of Interest [authors to provide own statement, .doc(x) format preferred]
Click here to download Disclosure-Conflict of Interest [authors to provide own statement, .doc(x) format preferred]: Conflict of Interest statement.docx
 
Please see a point by point response (in blue) to the reviewer’s comments 
Reviewer #1:  
This study described literature reviews of many studies of diffusion and perfusion 
weighted magnetic resonance imaging methods in non-enhanced gliomas. The authors 
concluded that rCBY can provide a rigorous assessment for gliomas and act as a 
potential imaging marker of malignancy and degree of tumor angiogenesis. This study 
is well organized and suggests both diffusion and perfusion imaging can promote the 
accuracy in diagnosis of gliomas. I think it deserve to publication of this journal. 
 
We would like to thank for the reviewer’s encouraging comments about our manuscript.  
Reviewer #2:  
 
It has been a pleasure to review your manuscript. It is a well written, organised, and 
interesting review. The main concern that I have about the paper is related to the 
conclusion. Although the abstract and the introduction are very hopeful, in the end, the 
conclusion gives the idea that nowadays every parameter still being useless. It maybe 
could be remarked or proposed how can we use them with current evidence although 
future studies still being necessaries. 
 
We thank the reviewer for the helpful comments. As indicated in response to the minor 
comments below, the conclusion has been changed appropriately 
 
1- Abstract: Your work is well resumed in the abstract, however, it promised more 
clinical usefulness than the provided in the work ¨ This review focuses on the utility 
of these methods for better characterisation and grading of non-enhancing 
gliomas, as it is more difficult to accurately devise an optimal treatment strategy 
for these tumours in comparison to enhancing gliomas¨  
 
We would like to thank the reviewer for the observation and have hence rephrased 
the abstract accordingly. The revised text states that, “This review focuses on the 
utility of these methods for better characterisation and grading of non-enhancing 





 paragraph again a clinical decision aid is promised but it is not clearly 
found in the paper: ¨The development of advanced imaging techniques, such as 
diffusion tensor imaging (DTI) and perfusion MRI, has enabled more sensitive 
tumour characterisation and grading than conventional MRI [4, 13]. These 
methods provide information about tumour cellularity, proliferation, disruption of 
white matter, tumour vascularity and vessel permeability [14, 15] and, as such, 
could allow for improved tumour grading [4, 16]. Therefore, the purpose of this 
review is to examine recent results using diffusion and perfusion methods for 




We believe that inclusion of diffusion and perfusion weighted imaging can aid in 
better diagnosis and hence clinical decision making with regards to the optimal 
choice of treatment strategies. We agree with the reviewer though, that we have not 
specifically provided a tool for the decision making and hence have deleted this 
phrase in the revised manuscript. 
 
3- Discussion: 
- Perfusion techniques paragraph 1: It is not said if CBF increase or decrease in 
LGG or HGG. 
 
The text has been revised to indicate that CBF increases in HGG. 
- Although every parameter is well explained, and supported by references, it is not 
clear which evidence is stronger and there are contradictory results between 
different papers.  
As this is a review, we wanted to present an unbiased coverage of the literature. 
As the reviewer rightly points out, some of the data seems to be mixed with one 
paper describing potential utility of a particular parameter, while the other 
showing no value in differentiation. However, it is to be noted that the literature is 
not contradictory in the sense that opposing trends (higher or lower) are not 
reported for any particular parameter. As the trends are generally similar, we 
believe that the discrepancy in results are primarily due to differences in data 
analysis or in choice of experimental groups (including astrocytomas and 
oligodendrogliomas, for example) rather than the underlying insensitivity of the 
diffusion or perfusion imaging based parameter. We therefore recommend a 
standard set of imaging and analysis parameters to be used in a multi-centre 
prospective trial to establish the role of these parameters in non-enhancing 
gliomas. We have revised to text to further elaborate this point. 
 
- At the end of diffusion studies there is an interesting resume :¨ To conclude the 
findings of diffusion imaging, even though some evidence suggests that these 
methods are useful in assessing tissue microstructure and heterogeneity in brain 
tumours, none of the diffusion parameters in isolation have been suggested to 
conclusively differentiate between non-enhancing LGGs and HGGs¨.  
But, to sum up, what happen if we combine them? Can we do this with reliable 
results? Which parameters are more useful to be combined? 
 
We would like to thank the reviewer for an excellent suggestion, and we do agree 
that combining the parameters are likely to provide more reliable results. As MD 
and FA are the most commonly used DTI parameters, we believe that combining 
these parameters with conventional imaging as well as perfusion imaging will be 
more useful. The text has been revised to add this statement 
 
- Think about the possible utility of summarise the information in a table. It could 
be helpful if a table with a column for the parameters, a column for the measured 
aspect (cellularity, blood supply…), a column for values in HGGs, other for 
LGGs and other for the utility/reliability/evidence or limits of each parameter.  
As suggested, we have included a table to summarize the diffusion and perfusion 
imaging parameters in high and low grade gliomas. The table also includes the 
references indicating the evidence as suggested.  
 
- It could also be very interesting any kind of decision algorithm by using the 
parameters; any advice to use ones parameters instead of others, which of them 
are more promising, or which combinations are better when we face non-
enhancing tumours in our clinical practice could be a wonderful and practical 
contribution. 
 
We agree that a decision making tool/algorithm combining the various imaging 
parameters is highly desirable for a better diagnosis of non-enhancing gliomas in 
the clinical practise. This could use simplistic statistical methods such a logistic 
regression analyses to find the best combination of imaging parameters or use 
more sophisticated image analysis methods such as machine learning, artificial 
neural networks, artificial intelligence and deep learning. The discussion has 
been revised to include this aspect along with some relevant references 
 
 
4- Conclusion:  
It is a good conclusion that also remarks the study´s limits, although I miss a 
conclusion with some clinical useful information as was promised in the abstract, 
and in the introduction.  
Please see our responses above about making the changes in the abstract and 
introduction. Accordingly, we have revised the conclusión to state:  
Both diffusion and perfusion imaging methods continue to aid in the accurate diagnosis 
of brain tumours; however, their role in assessing non-enhancing gliomas is still in its 
infancy, and the few early promising reports need to be validated in a large cohort of 
patients, preferably studied using a standardised, multi-central imaging trial. 
 
5- References: 
- The reference style inside the text is not the recommended from the journal as 
superscripts are preferred.  
- The reference style is not completely correct and DOI should be included. 
The references have been reformatted according to the journal style 
 
- Reference number 60, is cited in figure 4 but not in the text. 
This has been included 
- There are a couple of recent papers that could be interesting for your work. 
a. Eur Radiol. 2020 Apr;30(4):2142-2151. doi: 10.1007/s00330-019-06548-3. Epub 
2019 Dec 11. 
Diffusion- and perfusion-
weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) muta


















b. Asian J Neurosurg. 2019 Jan-Mar;14(1):47-51. doi: 10.4103/ajns.AJNS_191_16. 
Role of Diffusion and Perfusion Magnetic Resonance Imaging in Predicting the H

















We thank the reviewer for the suggestions, these references have been added 
6- Images: Beautiful images. 
 
We thank the reviewer for the encouraging remarks 
 
List of abbreviations: 
 
 
ADC         =     Apparent Diffusion Coefficient 
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Routine diagnostic magnetic resonance imaging (MRI) utilises enhancement of the tumour tissue as a 
marker of malignancy in intracranial gliomas. However, several high-grade tumours do not exhibit 
enhancement and conversely, some low-grade gliomas do demonstrate enhancement. Hence, conventional 
MRI has a limited role in the accurate grading of gliomas. Advanced MRI methods that evaluate the 
tissue microstructure and tumour haemodynamics provide a better understanding of tumour biology and 
promise to provide more accurate grading. These advanced MRI methods include diffusion-weighted 
imaging (DWI), diffusion tensor imaging (DTI), diffusion-kurtosis imaging (DKI), arterial spin labelling 
(ASL) imaging, dynamic-susceptibility contrast (DSC) imaging and  dynamic contrast-enhanced (DCE) 
imaging. This review focuses on the utility of these methods for better characterisation and 
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Introduction: 
Primary tumours arising in the central nervous system (CNS) are known as gliomas. The World Health 
Organisation (WHO) classification system is typically used to classify and grade CNS tumours based 
primarily on histological features of the tumour tissue, and it was updated in 2016 to include molecular 
markers as well 
[1, 2]
. Typically, gliomas of grades I and II are considered low-grade gliomas (LGGs), 
while gliomas of grades III and IV are considered high-grade gliomas (HGGs) 
[3]
 due to the difference in 
treatment of low- versus high-grade gliomas. However, accurate differentiation of tumour malignancy can 
only be obtained through stereotactic biopsy or resected tumour tissue, which is associated with morbidity 
[4]
. The risk of sampling error and the impact of the neuropathologist’s experience on the outcomes are 




Conventional MRI is often used for the detection and diagnosis of brain tumours
 [6]
. Most clinical brain 
tumour MRI protocols include T1- and T2-weighted images, fluid-attenuated inversion recovery (FLAIR) 
images and gadolinium enhanced T1-weighted images (Figure 1). These images help determine the 
location, size and extent of the tumour 
[7]
. Contrast enhancement using gadolinium-based contrast agents 
is indicative of the breakdown of the blood brain barrier (BBB). Generally, the accumulation of the 
contrast agent indicates whether the lesion is high-grade (presence) or low-grade (absence) 
[8, 9]
. However, 
malignancy is also exhibited by nearly a third of non-enhancing gliomas, while enhancement is observed 
in certain LGGs 
[9, 10]





In conventional MRI, LGGs appear as a homogenous mass and seldom exhibit peritumoural oedema or 
contrast enhancement 
[12]
. In contrast, HGGs reveal heterogeneous contrast enhancement with regions of 
necrosis, haemorrhage, extensive peritumoural oedema and cystic regions 
[7]
. These features are 
attributed to the cellular characteristics of HGGs, which include both grade III and IV glial tumours.  
Grade III  tumours are characterised by mitotic and anaplastic cells and are most frequently diagnosed as 
anaplastic astrocytomas (AAs). On the other hand, grade IV gliomas reveal elevated vascularity and 
cellularity with enhanced necrotic appearance and are usually labelled as glioblastoma multiforme 
(GBM). Overall, the imaging features observed in LGGs and HGGs are not specific to a particular grade. 
In some cases, LGGs may display similar morphological features to HGGs, and the latter may present 
relatively benign imaging findings 
[13, 14]
, leading to inaccurate tumour staging. The necessity of accurate 
grading is exacerbated in non-enhancing gliomas because critical treatment decisions need to be made. 
Surgery and chemotherapy represent the preferred treatments for HGGs, while a wait-and-watch approach 
is generally used to treat LGGs. Therefore, to overcome the shortcomings of conventional MRI, advanced 
imaging has been employed to enable quantitative analysis and improve the accuracy of diagnosis. 
The development of advanced imaging techniques, such as diffusion tensor imaging (DTI) and perfusion 
MRI, has enabled more sensitive tumour characterisation and grading than conventional MRI 
[4, 13]
. These 
methods provide information about tumour cellularity, proliferation, disruption of white matter, tumour 
vascularity and vessel permeability
 [14, 15]
 (summarized in Table 1) and, as such, could allow for improved 
tumour grading 
[4, 16]
. Therefore, the purpose of this review is to examine recent results using diffusion 
and perfusion methods for tumour characterisation and grading non-enhancing gliomas. 
 
 
Diffusion techniques:  
Diffusion-weighted imaging (DWI) is predominantly used within neuroimaging as well as in oncological 
applications outside the brain. Standard DWI methods incorporate Einstein's original concept that the 
diffusion of water molecules follows a Gaussian (normal) distribution 
[17]
. Typically, DWI measures 
random water molecular movement in tissue, and its derived parameter, apparent diffusion coefficient 
(ADC), represents direction-independent water displacement. DWI can provide information about tissue 
microstructure without the use of exogenous contrast agents 
[18]
. Previous studies using DWI reported a 
strong association between ADC and cell density 
[18, 19]
. It has been shown that within brain tumour tissue 
(high cellularity), free water motion is restricted and the measured ADC is low, whereas in normal brain 




The utility of ADC in characterising non-enhancing gliomas has also been investigated.  One study 
reported that ADC values were significantly lower in HGGs compared to LGGs 
[21]
. Another study 
observed lower ADC values in the solid portions of non-enhancing HGGs compared to LGGs 
[22]
, which 
suggested that ADC values were useful in differentiating between non-enhancing HGGs and LGGs. 
However, no significant differences in the ADC values of the peritumoural regions were observed in this 
study 
[22]
. Despite these promising findings, mixed findings have also been reported with regard to the 
ability of ADC to differentiate LGGs from HGGs. Higher ADC values have been noted in LGGs due to 
their cellular morphology 
[23, 24]
, but overlapping ADC values between the two groups have also been 
reported. One study highlighted the absence of significant differences despite the higher ADC values in 
LGGs 
[25]
. This finding was supported by a second study that reported a lack of significant differences in 
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The lack of significant differences in ADC values may be due to the simplistic analysis of DWI data using 
a mono-exponential fitting. The diffusion of water molecules in tumour tissues is much more complicated 
than in free water due to the complex cellular structures within the tumour microenvironment, which 
impacts barriers to diffusion. Consequently, the displacement probability of water in tumour tissue may 
substantially deviate from the conventionally used Gaussian form. Therefore, alternate diffusion models 
have been proposed to account for the non-Gaussian diffusion behaviour to facilitate a more 




Diffusion kurtosis imaging (DKI) is a diffusion imaging technique that does not assume Gaussian 
distribution of water molecules and measures deviation from Gaussian behaviour. It has been proposed to 
more accurately characterise the complicated water diffusion in biological tissues. It provides additional 
information about tumour heterogeneity by measuring kurtosis metrics, including the mean kurtosis 
(MK), axial kurtosis (AK) and  radial kurtosis (RK), as seen in Figure 2 
[27, 28]
. These parameters represent 
the mean deviation from Gaussianity, the directional deviation from Gaussianity along the axial diffusion 
direction and the directional deviation perpendicular to the axial diffusion direction 
[29]
.   
A previous study assessed the contribution of DKI parameters, and demonstrated that all DKI parameters 
were significantly higher in HGGs when contrasted against LGGs 
[30]
. The same study reported that these 
parameters were also significant different between grades I and II and between grades II and IV 
[30]
. 
Tietze et al. also noted that all DKI exhibited significantly higher values in HGGs compared to LGGs 
[31]
. 
Another study noted that the average MK value was significantly higher in the tumour cores of HGGs 
compared to those of LGGs 
[32]
. However, another study reported that DKI variables did not differ 
significantly between grades II and III 
[33]
. Despite these early promising findings, we are unaware of any 
studies specifically evaluating the utility of DKI in differentiating non-enhancing gliomas, and hence its 
role in these gliomas remains speculative. 
 
The complex yet organised structure of the central nervous system (CNS), including myelinated and 
unmyelinated axons, cellular membrane, and the presence of proteins and intracellular organelles affect 
water diffusion inside the CNS. These factors could substantially impact the water diffusion pattern in the 
CNS, which can be broadly classified into isotropic and anisotropic diffusion 
[28]
. Therefore, advanced 
diffusion models using diffusion tensor imaging (DTI) have been proposed to account for diffusion 




DTI determines the directionality of diffusion and provides additional information on the microstructure 
of the brain 
[27]
. It involves acquisition of diffusion-weighted images in at least six diffusion gradient 
directions. The motion of water molecules on the X, Y and  Z axes is assessed based on a calculation of 
three diffusion tensor eigenvalues, namely, λ1, λ2 and  λ3 
[12, 17]
. The fractional anisotropy (FA), which 
measures the tendency of water molecules for diffusion in a particular direction, and the magnitude of 
diffusion (MD) represent the two most commonly studied DTI parameters. MD is mathematically 
analogous to the ADC value estimated by conventional DWI experiments. Furthermore, axial diffusion 
(AD) and radial diffusion (RD) denote the rate of diffusion along the primary diffusion axis and in the 




FA values have been utilised in the grading of gliomas and in demonstrating tumour infiltration in the 
normal brain. Various studies have reported the ability of FA to differentiate between different glioma 
grades 
[37-39]
. HGGs demonstrated significantly higher FA values than those in LGGs, with a threshold FA 
value of 0.188 differentiated between LGGs and HGGs 
[37]
. This study also reported a positive 
relationship between glioma cell density and FA. However, previous research has noted a negative 
relationship between glioma cell density and FA 
[38, 40]
. Another study indicated a lack of significant 
differences between anaplastic astrocytomas and LGGs 
[41]
. Utility of FA in the grading of non-enhancing 
gliomas has also been evaluated. A previous study suggested a cut-off value of 0.129 to separate HGGs 
from LGGs, with significantly lower FA values exhibited in LGGs 
[16]
. However, another study indicated 
a lack of significant differences in FA values between LGGs and HGGs from non-enhancing areas of the 
tumour 
[42]





MD reflects directionally averaged diffusivity of water, which is sensitive to oedema, cellularity and  
necrosis, Table 1
 [44]
 and was found to be significantly lower in HGGs compared to LGGs 
[25]
. Another 
study reported that grade I gliomas exhibited significantly higher MD in comparison to grade III and IV 
gliomas, whilst there was a lack of difference in MD values between grade II and III gliomas 
[37]
. With 
regard to non-enhancing gliomas, Lee et al. demonstrated that even non-enhancing areas of HGGs 
demonstrated a significantly lower MD compared to LGGs 
[42]
. This result was further supported by Liu et 
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al. however, their findings did not reach statistical significance 
[16]
. On the other hand, another study 





Several studies have suggested that axonal integrity/degeneration can be identified through AD, while 
myelin damage can be identified with RD
 [45, 46]
. Published studies suggest that AD and RD were capable 
of differentiating between HGGs and LGGs 
[25, 43]
. Yuan et al.
 [47]
 reported  that the RD and AD values 
were significantly higher in LGGs than in HGGs. Another study noted that LGGs exhibited significantly 
higher RD and AD values when contrasted against HGGs, and this result considered differences between 
gliomas grades II and III and between grades II and IV 
[25]
. In regard to non-enhancing gliomas, one study 




To conclude the findings of diffusion imaging, even though some evidence suggests that these methods 
are useful in assessing tissue microstructure and heterogeneity in brain tumours, none of the diffusion 
parameters in isolation have been suggested to conclusively differentiate between non-enhancing LGGs 
and HGGs. However, we believe that by combining the information from the most commonly used DTI 
parameters, MD and FA, with conventional imaging as well as perfusion imaging (as discussed below) 
might aid in the accurate grading of non-enhancing gliomas. Besides having a heterogeneous structural 
microenvironment, brain tumours are also known to have a complex and heterogeneous vasculature, 
relying on angiogenesis to maintain an adequate blood supply. MRI-based perfusion imaging methods 
can provide information about tumour vasculature and thus may be able to aid in accurate tumour 
grading.  
 
Perfusion techniques:   
Perfusion MRI methods provide estimates of how well a tissue is supplied with blood. Perfusion MRI can 
be broadly classified into two methods: one that uses an endogenous contrast agent (water) to measure 
blood flow and another that uses an exogenous contrast agent, typically gadolinium-based contrast agents 
(GBCA), to study contrast kinetics. The first method is generally referred to as arterial spin labelling 
(ASL), which is a completely non-invasive MRI technique that measures blood flow by using 
magnetically labelled water protons in arterial blood as an endogenous tracer 
[48]
. The parameter most 
commonly derived from ASL methods is cerebral blood flow (CBF).  The relative rCBF has been used to 
discriminate between low- and high-grade gliomas. Some studies suggest that HGGs demonstrate 
significantly higher rCBF values than those in LGGs
 [49, 50]
. Another study reported a strong correlation 
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between ASL-derived CBF values and dynamic susceptibility contrast (DSC)-derived CBF values in 
brain tumours
 [51]
. However, one study found that the correlation between DSC-derived rCBF and ASL-
derived rCBF was weaker 
[49]
. To our knowledge, the use of ASL in evaluating non-enhancing gliomas 
has not been investigated.  
 
Whilst ASL has the advantage of being completely non-invasive, it suffers from low signal-to-noise ratio 
as well as sensitivity to motion since it is a difference method in which ‘labelled’ images are subtracted 
from ‘control’ images 
[52]
. The more commonly used perfusion imaging method uses an exogenous 
contrast agent and can either be performed using dynamic contrast enhanced (DCE) or dynamic 
susceptibility contrast (DSC) enhanced imaging. DCE imaging relies on the acquisition of T1-weighted 
images and this method detects changes in MR signal as the contrast agent passes through the blood 
vessels and leaks into the interstitial space during the BBB breakdown. Hence, the images obtained 
through this method can be indicative of microvascular properties such as vascular permeability and flow 




. DCE-MRI has been evaluated to discriminate between 
gliomas of different grades. The K
trans
 parameter can be used to quantify the permeability of tumour 
vessels, as shown in Figure 4 
[54]
. This study reported that the skewness of K
trans
 was superior in 
differentiating between grade II and grade III gliomas 
[55]
. In addition, significantly higher K
trans
  was 
reported in HGGs compared to LGGs 
[54, 56–58]
. It should be noted that K
trans
 reflects a combination of 
microvascular blood flow, vessel permeability and  vessel density. These factors are correlated with the 
distribution of tumour vessels and abnormal permeability 
[59, 60]
, indicating that contrast agents permeate 
more easily in HGGs than in LGGs. To our knowledge, DCE-MRI studies have not been reported in non-
enhancing gliomas. 
 
In DSC imaging, haemodynamic parameters are measured by studying the changes in MR intensity 
during the initial passage of the paramagnetic contrast agent 
[28, 61]
. The cerebral blood volume (CBV), 
cerebral blood flow (CBF) and  mean transit time (MTT) constitute the main hemodynamic parameters 
associated with DSC-MRI. Indicative of the blood supply of a particular region of tissue at a particular 
moment, the CBV can be derived from the area under the fitted curve. Meanwhile, the CBV-to-MTT ratio 
reflects CBF. As the change in signal intensity and the gadolinium concentration is not linearly correlated, 
it is challenging to quantitatively measure these parameters. Hence, they are typically normalised to the 
contralateral white matter and the values are represented as ‘relative’ (rCBV, rCBF and rMTT), as 
depicted in Figure 5 
[62, 63]
. DSC has been shown to differentiate between LGGs and HGGs. Some studies 
have reported that rCBV values aid in differentiation between various glioma grades by recognising 
histopathological features, including vascularisation and the degree of angiogenesis, Table 1 
[64, 65]
. The 
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rCBV values of LGGs were negligible or very low, indicating minimal vascularisation when contrasted 
against HGGs. Anaplastic astrocytomas demonstrated higher rCBV values compared to LGGs, but these 
values were lower than in GBMs, the latter representing gliomas with the greatest level of 
hypervascularisation. Several studies have also reported variation in the degree of vascularisation of 
LGGs and HGGs
 [16, 66-69]
. Despite the range of rCBV values reported in the literature amongst various 
types of gliomas, the commonality was the observation of higher rCBV in gliomas, which was likely due 
to the associated micro-vascular density noted in each grade. It is important to realise that gliomas 
constitute a heterogeneous range of tumours and overlap in rCBV values should be expected. For 
example, even low-grade oligodendrogliomas have been noted to have higher angiogenesis, which 
correlated with higher rCBV values than typically reported in HGGs 
[16, 70, 71]
.  
Utilising DSC derived parameters to differentiate between non-enhancing LGGs and HGGs has led to 
ambiguous findings. Liu et al. reported a lack of significant differences in rCBV ratios between LGGs and 
HGGs 
[16]
, whereas, Fan et al. noted significantly  higher rCBV values in non-enhancing areas of HGGs 
than in LGGs 
[72]
. The latter study also noted significant variation in rCBV values in peritumoural regions 
[72]
. This was supported by a study that reported statistically higher rCBVmax ratios for grade III 
astrocytomas compared to grade I or grade II astrocytomas 
[11]
. However, previous studies also 





With regard to the utility of MTT and DSC-derived rCBF values in non-enhancing gliomas, one study 
reported significant differences in rCBF and rMTT between grade II and GBM 
[43]
. However, in the same 
study, no significant differences in rCBF and rMTT were noted between grade II and grade III non-
enhancing gliomas 
[43]
. Another study reported significant differences in rCBF values between these two 
grades of gliomas 
[74]
. This finding was further supported by a study that reported higher rCBF values 




Despite the observed variability in results, which may in part be due to a small sample size, 
methodological differences or  the inclusion of different histological sub-types of gliomas, it is generally 
accepted that rCBV provides a rigorous means of assessing gliomas, thereby allowing it to act as a 
potential imaging marker of malignancy and degree of tumour angiogenesis, at least for enhancing 
tumours.  
 
We acknowledge that the current literature, with mixed results about the utility of diffusion and perfusion 
imaging in non-enhancing gliomas is still emerging, but we believe that the data is not contradictory in 
the sense that opposing values (higher or lower between HGG and LGG) are not reported for any 
particular parameter. As the trends are generally similar between different studies, we believe that the 
apparent discrepancy is primarily due to differences in data analysis or in choice of experimental groups 
(including astrocytomas and oligodendrogliomas together, for example) rather than the underlying 
insensitivity of the diffusion or perfusion imaging based parameter. We therefore recommend a standard 
set of imaging and analysis parameters evaluated in a homogenous histological subgroup, to be used in a 
multi-centre prospective trial to establish the role of these parameters in non-enhancing gliomas. In 
addition, a decision-making tool/algorithm combining the various imaging parameters is highly desirable 
for a better diagnosis of non-enhancing gliomas in the clinical practise. This could use simplistic 
statistical methods such a logistic regression analyses to find the best combination of imaging parameters 
or use more sophisticated image analysis methods such as machine learning, artificial neural networks, 




Both diffusion and perfusion imaging methods continue to aid in the accurate diagnosis of brain tumours; 
however, their role in assessing non-enhancing gliomas is still in its infancy, and the few early promising 
reports need to be validated in a large cohort of patients, preferably studied using a standardised, multi-
center imaging trial. 
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Figure 1: MR images of a patient with a grade III anaplastic astrocytoma who underwent conventional diagnostic 
MRI. (A) axial T1-weighted pre-contrast, (B) T2 and  (C) T1 post-contrast images. No contrast agent enhancement 
was observed in this patient.  
 
 
Figure 2: Representative diffusion kurtosis images from a patient with an oligodendroglioma grade II in the right 
frontal lobe. (A) axial kurtosis, (B) axial diffusivity and  (C) radial kurtosis [33]. 
 
 
Figure 3: Representative DTI-derived parametric maps from a patient with a grade II astrocytoma. In FA, the white 
matter (WM) appears hyper-intense, while the cerebrospinal fluid (CSF) and the tumour appear hypo-intense. In 
contrast, in MD, AD and  RD, the CSF and the tumour are hyper-intense, while the WM appears hypo-intense.  
 
 
Figure 4: Follow-up MRI of a left frontal primary GBM treated by surgery and stereotactic radiosurgery (SRS). (A) 
axial contrast-enhanced T1-weighted image demonstrating the enhancing tumour in the frontal lobe, (B) The 
relative cerebral blood volume rCBV colorimetric map overlaid on the MR image and (C) pixel-by-pixel Ktrans 
colorimetric map showing heterogenous K
trans
 values from the tumour [60]. 
 
Figure 5: DSC maps showing the tumour (arrow) from a patient with grade II (A) and grade III (B) glioma. The 
CBV and CBF maps in (A) show elevated blood volume and blood flow within the tumour (8.16 mL/100 mL
2
, 111 
ml/100 g, respectively) compared with the normal WM (4.9 mL/100 mL
2
, 71.4 mL/100 g/min, respectively). 
 
Diffusion and perfusion weighted magnetic resonance imaging methods in 
non-enhancing gliomas 
 























*Manuscript (Must be in .doc or .docx format)
Click here to download Manuscript (Must be in .doc or .docx format): Hatham_Alkanhal_clean.docxClick here to view linked References
Abstract: 
Routine diagnostic magnetic resonance imaging (MRI) utilises enhancement of the tumour tissue as a 
marker of malignancy in intracranial gliomas. However, several high-grade tumours do not exhibit 
enhancement and conversely, some low-grade gliomas do demonstrate enhancement. Hence, conventional 
MRI has a limited role in the accurate grading of gliomas. Advanced MRI methods that evaluate the 
tissue microstructure and tumour haemodynamics provide a better understanding of tumour biology and 
promise to provide more accurate grading. These advanced MRI methods include diffusion-weighted 
imaging (DWI), diffusion tensor imaging (DTI), diffusion-kurtosis imaging (DKI), arterial spin labelling 
(ASL) imaging, dynamic-susceptibility contrast (DSC) imaging and  dynamic contrast-enhanced (DCE) 
imaging. This review focuses on the utility of these methods for better characterisation and 

































Primary tumours arising in the central nervous system (CNS) are known as gliomas. The World Health 
Organisation (WHO) classification system is typically used to classify and grade CNS tumours based 
primarily on histological features of the tumour tissue, and it was updated in 2016 to include molecular 
markers as well 
[1, 2]
. Typically, gliomas of grades I and II are considered low-grade gliomas (LGGs), 
while gliomas of grades III and IV are considered high-grade gliomas (HGGs) 
[3]
 due to the difference in 
treatment of low- versus high-grade gliomas. However, accurate differentiation of tumour malignancy can 
only be obtained through stereotactic biopsy or resected tumour tissue, which is associated with morbidity 
[4]
. The risk of sampling error and the impact of the neuropathologist’s experience on the outcomes are 




Conventional MRI is often used for the detection and diagnosis of brain tumours
 [6]
. Most clinical brain 
tumour MRI protocols include T1- and T2-weighted images, fluid-attenuated inversion recovery (FLAIR) 
images and gadolinium enhanced T1-weighted images (Figure 1). These images help determine the 
location, size and extent of the tumour 
[7]
. Contrast enhancement using gadolinium-based contrast agents 
is indicative of the breakdown of the blood brain barrier (BBB). Generally, the accumulation of the 
contrast agent indicates whether the lesion is high-grade (presence) or low-grade (absence) 
[8, 9]
. However, 
malignancy is also exhibited by nearly a third of non-enhancing gliomas, while enhancement is observed 
in certain LGGs 
[9, 10]





In conventional MRI, LGGs appear as a homogenous mass and seldom exhibit peritumoural oedema or 
contrast enhancement 
[12]
. In contrast, HGGs reveal heterogeneous contrast enhancement with regions of 
necrosis, haemorrhage, extensive peritumoural oedema and cystic regions 
[7]
. These features are 
attributed to the cellular characteristics of HGGs, which include both grade III and IV glial tumours.  
Grade III  tumours are characterised by mitotic and anaplastic cells and are most frequently diagnosed as 
anaplastic astrocytomas (AAs). On the other hand, grade IV gliomas reveal elevated vascularity and 
cellularity with enhanced necrotic appearance and are usually labelled as glioblastoma multiforme 
(GBM). Overall, the imaging features observed in LGGs and HGGs are not specific to a particular grade. 
In some cases, LGGs may display similar morphological features to HGGs, and the latter may present 
relatively benign imaging findings 
[13, 14]
, leading to inaccurate tumour staging. The necessity of accurate 
grading is exacerbated in non-enhancing gliomas because critical treatment decisions need to be made. 
Surgery and chemotherapy represent the preferred treatments for HGGs, while a wait-and-watch approach 
is generally used to treat LGGs. Therefore, to overcome the shortcomings of conventional MRI, advanced 
imaging has been employed to enable quantitative analysis and improve the accuracy of diagnosis. 
The development of advanced imaging techniques, such as diffusion tensor imaging (DTI) and perfusion 
MRI, has enabled more sensitive tumour characterisation and grading than conventional MRI 
[4, 13]
. These 
methods provide information about tumour cellularity, proliferation, disruption of white matter, tumour 
vascularity and vessel permeability
 [14, 15]
 (summarized in Table 1) and, as such, could allow for improved 
tumour grading 
[4, 16]
. Therefore, the purpose of this review is to examine recent results using diffusion 
and perfusion methods for tumour characterisation and grading non-enhancing gliomas. 
 
 
Diffusion techniques:  
Diffusion-weighted imaging (DWI) is predominantly used within neuroimaging as well as in oncological 
applications outside the brain. Standard DWI methods incorporate Einstein's original concept that the 
diffusion of water molecules follows a Gaussian (normal) distribution 
[17]
. Typically, DWI measures 
random water molecular movement in tissue, and its derived parameter, apparent diffusion coefficient 
(ADC), represents direction-independent water displacement. DWI can provide information about tissue 
microstructure without the use of exogenous contrast agents 
[18]
. Previous studies using DWI reported a 
strong association between ADC and cell density 
[18, 19]
. It has been shown that within brain tumour tissue 
(high cellularity), free water motion is restricted and the measured ADC is low, whereas in normal brain 




The utility of ADC in characterising non-enhancing gliomas has also been investigated.  One study 
reported that ADC values were significantly lower in HGGs compared to LGGs 
[21]
. Another study 
observed lower ADC values in the solid portions of non-enhancing HGGs compared to LGGs 
[22]
, which 
suggested that ADC values were useful in differentiating between non-enhancing HGGs and LGGs. 
However, no significant differences in the ADC values of the peritumoural regions were observed in this 
study 
[22]
. Despite these promising findings, mixed findings have also been reported with regard to the 
ability of ADC to differentiate LGGs from HGGs. Higher ADC values have been noted in LGGs due to 
their cellular morphology 
[23, 24]
, but overlapping ADC values between the two groups have also been 
reported. One study highlighted the absence of significant differences despite the higher ADC values in 
LGGs 
[25]
. This finding was supported by a second study that reported a lack of significant differences in 





The lack of significant differences in ADC values may be due to the simplistic analysis of DWI data using 
a mono-exponential fitting. The diffusion of water molecules in tumour tissues is much more complicated 
than in free water due to the complex cellular structures within the tumour microenvironment, which 
impacts barriers to diffusion. Consequently, the displacement probability of water in tumour tissue may 
substantially deviate from the conventionally used Gaussian form. Therefore, alternate diffusion models 
have been proposed to account for the non-Gaussian diffusion behaviour to facilitate a more 




Diffusion kurtosis imaging (DKI) is a diffusion imaging technique that does not assume Gaussian 
distribution of water molecules and measures deviation from Gaussian behaviour. It has been proposed to 
more accurately characterise the complicated water diffusion in biological tissues. It provides additional 
information about tumour heterogeneity by measuring kurtosis metrics, including the mean kurtosis 
(MK), axial kurtosis (AK) and  radial kurtosis (RK), as seen in Figure 2 
[27, 28]
. These parameters represent 
the mean deviation from Gaussianity, the directional deviation from Gaussianity along the axial diffusion 
direction and the directional deviation perpendicular to the axial diffusion direction 
[29]
.   
A previous study assessed the contribution of DKI parameters, and demonstrated that all DKI parameters 
were significantly higher in HGGs when contrasted against LGGs 
[30]
. The same study reported that these 
parameters were also significant different between grades I and II and between grades II and IV 
[30]
. 
Tietze et al. also noted that all DKI exhibited significantly higher values in HGGs compared to LGGs 
[31]
. 
Another study noted that the average MK value was significantly higher in the tumour cores of HGGs 
compared to those of LGGs 
[32]
. However, another study reported that DKI variables did not differ 
significantly between grades II and III 
[33]
. Despite these early promising findings, we are unaware of any 
studies specifically evaluating the utility of DKI in differentiating non-enhancing gliomas, and hence its 
role in these gliomas remains speculative. 
 
The complex yet organised structure of the central nervous system (CNS), including myelinated and 
unmyelinated axons, cellular membrane, and the presence of proteins and intracellular organelles affect 
water diffusion inside the CNS. These factors could substantially impact the water diffusion pattern in the 
CNS, which can be broadly classified into isotropic and anisotropic diffusion 
[28]
. Therefore, advanced 
diffusion models using diffusion tensor imaging (DTI) have been proposed to account for diffusion 




DTI determines the directionality of diffusion and provides additional information on the microstructure 
of the brain 
[27]
. It involves acquisition of diffusion-weighted images in at least six diffusion gradient 
directions. The motion of water molecules on the X, Y and  Z axes is assessed based on a calculation of 
three diffusion tensor eigenvalues, namely, λ1, λ2 and  λ3 
[12, 17]
. The fractional anisotropy (FA), which 
measures the tendency of water molecules for diffusion in a particular direction, and the magnitude of 
diffusion (MD) represent the two most commonly studied DTI parameters. MD is mathematically 
analogous to the ADC value estimated by conventional DWI experiments. Furthermore, axial diffusion 
(AD) and radial diffusion (RD) denote the rate of diffusion along the primary diffusion axis and in the 




FA values have been utilised in the grading of gliomas and in demonstrating tumour infiltration in the 
normal brain. Various studies have reported the ability of FA to differentiate between different glioma 
grades 
[37-39]
. HGGs demonstrated significantly higher FA values than those in LGGs, with a threshold FA 
value of 0.188 differentiated between LGGs and HGGs 
[37]
. This study also reported a positive 
relationship between glioma cell density and FA. However, previous research has noted a negative 
relationship between glioma cell density and FA 
[38, 40]
. Another study indicated a lack of significant 
differences between anaplastic astrocytomas and LGGs 
[41]
. Utility of FA in the grading of non-enhancing 
gliomas has also been evaluated. A previous study suggested a cut-off value of 0.129 to separate HGGs 
from LGGs, with significantly lower FA values exhibited in LGGs 
[16]
. However, another study indicated 
a lack of significant differences in FA values between LGGs and HGGs from non-enhancing areas of the 
tumour 
[42]





MD reflects directionally averaged diffusivity of water, which is sensitive to oedema, cellularity and  
necrosis, Table 1
 [44]
 and was found to be significantly lower in HGGs compared to LGGs 
[25]
. Another 
study reported that grade I gliomas exhibited significantly higher MD in comparison to grade III and IV 
gliomas, whilst there was a lack of difference in MD values between grade II and III gliomas 
[37]
. With 
regard to non-enhancing gliomas, Lee et al. demonstrated that even non-enhancing areas of HGGs 
demonstrated a significantly lower MD compared to LGGs 
[42]
. This result was further supported by Liu et 
al. however, their findings did not reach statistical significance 
[16]
. On the other hand, another study 





Several studies have suggested that axonal integrity/degeneration can be identified through AD, while 
myelin damage can be identified with RD
 [45, 46]
. Published studies suggest that AD and RD were capable 
of differentiating between HGGs and LGGs 
[25, 43]
. Yuan et al.
 [47]
 reported  that the RD and AD values 
were significantly higher in LGGs than in HGGs. Another study noted that LGGs exhibited significantly 
higher RD and AD values when contrasted against HGGs, and this result considered differences between 
gliomas grades II and III and between grades II and IV 
[25]
. In regard to non-enhancing gliomas, one study 




To conclude the findings of diffusion imaging, even though some evidence suggests that these methods 
are useful in assessing tissue microstructure and heterogeneity in brain tumours, none of the diffusion 
parameters in isolation have been suggested to conclusively differentiate between non-enhancing LGGs 
and HGGs. However, we believe that by combining the information from the most commonly used DTI 
parameters, MD and FA, with conventional imaging as well as perfusion imaging (as discussed below) 
might aid in the accurate grading of non-enhancing gliomas. Besides having a heterogeneous structural 
microenvironment, brain tumours are also known to have a complex and heterogeneous vasculature, 
relying on angiogenesis to maintain an adequate blood supply. MRI-based perfusion imaging methods 
can provide information about tumour vasculature and thus may be able to aid in accurate tumour 
grading.  
 
Perfusion techniques:   
Perfusion MRI methods provide estimates of how well a tissue is supplied with blood. Perfusion MRI can 
be broadly classified into two methods: one that uses an endogenous contrast agent (water) to measure 
blood flow and another that uses an exogenous contrast agent, typically gadolinium-based contrast agents 
(GBCA), to study contrast kinetics. The first method is generally referred to as arterial spin labelling 
(ASL), which is a completely non-invasive MRI technique that measures blood flow by using 
magnetically labelled water protons in arterial blood as an endogenous tracer 
[48]
. The parameter most 
commonly derived from ASL methods is cerebral blood flow (CBF).  The relative rCBF has been used to 
discriminate between low- and high-grade gliomas. Some studies suggest that HGGs demonstrate 
significantly higher rCBF values than those in LGGs
 [49, 50]
. Another study reported a strong correlation 
between ASL-derived CBF values and dynamic susceptibility contrast (DSC)-derived CBF values in 
brain tumours
 [51]
. However, one study found that the correlation between DSC-derived rCBF and ASL-
derived rCBF was weaker 
[49]
. To our knowledge, the use of ASL in evaluating non-enhancing gliomas 
has not been investigated.  
 
Whilst ASL has the advantage of being completely non-invasive, it suffers from low signal-to-noise ratio 
as well as sensitivity to motion since it is a difference method in which ‘labelled’ images are subtracted 
from ‘control’ images 
[52]
. The more commonly used perfusion imaging method uses an exogenous 
contrast agent and can either be performed using dynamic contrast enhanced (DCE) or dynamic 
susceptibility contrast (DSC) enhanced imaging. DCE imaging relies on the acquisition of T1-weighted 
images and this method detects changes in MR signal as the contrast agent passes through the blood 
vessels and leaks into the interstitial space during the BBB breakdown. Hence, the images obtained 
through this method can be indicative of microvascular properties such as vascular permeability and flow 




. DCE-MRI has been evaluated to discriminate between 
gliomas of different grades. The K
trans
 parameter can be used to quantify the permeability of tumour 
vessels, as shown in Figure 4 
[54]
. This study reported that the skewness of K
trans
 was superior in 
differentiating between grade II and grade III gliomas 
[55]
. In addition, significantly higher K
trans
  was 
reported in HGGs compared to LGGs 
[54, 56–58]
. It should be noted that K
trans
 reflects a combination of 
microvascular blood flow, vessel permeability and  vessel density. These factors are correlated with the 
distribution of tumour vessels and abnormal permeability 
[59, 60]
, indicating that contrast agents permeate 
more easily in HGGs than in LGGs. To our knowledge, DCE-MRI studies have not been reported in non-
enhancing gliomas. 
 
In DSC imaging, haemodynamic parameters are measured by studying the changes in MR intensity 
during the initial passage of the paramagnetic contrast agent 
[28, 61]
. The cerebral blood volume (CBV), 
cerebral blood flow (CBF) and  mean transit time (MTT) constitute the main hemodynamic parameters 
associated with DSC-MRI. Indicative of the blood supply of a particular region of tissue at a particular 
moment, the CBV can be derived from the area under the fitted curve. Meanwhile, the CBV-to-MTT ratio 
reflects CBF. As the change in signal intensity and the gadolinium concentration is not linearly correlated, 
it is challenging to quantitatively measure these parameters. Hence, they are typically normalised to the 
contralateral white matter and the values are represented as ‘relative’ (rCBV, rCBF and rMTT), as 
depicted in Figure 5 
[62, 63]
. DSC has been shown to differentiate between LGGs and HGGs. Some studies 
have reported that rCBV values aid in differentiation between various glioma grades by recognising 
histopathological features, including vascularisation and the degree of angiogenesis, Table 1 
[64, 65]
. The 
rCBV values of LGGs were negligible or very low, indicating minimal vascularisation when contrasted 
against HGGs. Anaplastic astrocytomas demonstrated higher rCBV values compared to LGGs, but these 
values were lower than in GBMs, the latter representing gliomas with the greatest level of 
hypervascularisation. Several studies have also reported variation in the degree of vascularisation of 
LGGs and HGGs
 [16, 66-69]
. Despite the range of rCBV values reported in the literature amongst various 
types of gliomas, the commonality was the observation of higher rCBV in gliomas, which was likely due 
to the associated micro-vascular density noted in each grade. It is important to realise that gliomas 
constitute a heterogeneous range of tumours and overlap in rCBV values should be expected. For 
example, even low-grade oligodendrogliomas have been noted to have higher angiogenesis, which 
correlated with higher rCBV values than typically reported in HGGs 
[16, 70, 71]
.  
Utilising DSC derived parameters to differentiate between non-enhancing LGGs and HGGs has led to 
ambiguous findings. Liu et al. reported a lack of significant differences in rCBV ratios between LGGs and 
HGGs 
[16]
, whereas, Fan et al. noted significantly  higher rCBV values in non-enhancing areas of HGGs 
than in LGGs 
[72]
. The latter study also noted significant variation in rCBV values in peritumoural regions 
[72]
. This was supported by a study that reported statistically higher rCBVmax ratios for grade III 
astrocytomas compared to grade I or grade II astrocytomas 
[11]
. However, previous studies also 





With regard to the utility of MTT and DSC-derived rCBF values in non-enhancing gliomas, one study 
reported significant differences in rCBF and rMTT between grade II and GBM 
[43]
. However, in the same 
study, no significant differences in rCBF and rMTT were noted between grade II and grade III non-
enhancing gliomas 
[43]
. Another study reported significant differences in rCBF values between these two 
grades of gliomas 
[74]
. This finding was further supported by a study that reported higher rCBF values 




Despite the observed variability in results, which may in part be due to a small sample size, 
methodological differences or  the inclusion of different histological sub-types of gliomas, it is generally 
accepted that rCBV provides a rigorous means of assessing gliomas, thereby allowing it to act as a 
potential imaging marker of malignancy and degree of tumour angiogenesis, at least for enhancing 
tumours.  
 
We acknowledge that the current literature, with mixed results about the utility of diffusion and perfusion 
imaging in non-enhancing gliomas is still emerging, but we believe that the data is not contradictory in 
the sense that opposing values (higher or lower between HGG and LGG) are not reported for any 
particular parameter. As the trends are generally similar between different studies, we believe that the 
apparent discrepancy is primarily due to differences in data analysis or in choice of experimental groups 
(including astrocytomas and oligodendrogliomas together, for example) rather than the underlying 
insensitivity of the diffusion or perfusion imaging based parameter. We therefore recommend a standard 
set of imaging and analysis parameters evaluated in a homogenous histological subgroup, to be used in a 
multi-centre prospective trial to establish the role of these parameters in non-enhancing gliomas. In 
addition, a decision-making tool/algorithm combining the various imaging parameters is highly desirable 
for a better diagnosis of non-enhancing gliomas in the clinical practise. This could use simplistic 
statistical methods such a logistic regression analyses to find the best combination of imaging parameters 
or use more sophisticated image analysis methods such as machine learning, artificial neural networks, 




Both diffusion and perfusion imaging methods continue to aid in the accurate diagnosis of brain tumours; 
however, their role in assessing non-enhancing gliomas is still in its infancy, and the few early promising 
reports need to be validated in a large cohort of patients, preferably studied using a standardised, multi-
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Figure 1: MR images of a patient with a grade III anaplastic astrocytoma who underwent conventional diagnostic 
MRI. (A) axial T1-weighted pre-contrast, (B) T2 and  (C) T1 post-contrast images. No contrast agent enhancement 
was observed in this patient.  
 
 
Figure 2: Representative diffusion kurtosis images from a patient with an oligodendroglioma grade II in the right 
frontal lobe. (A) axial kurtosis, (B) axial diffusivity and  (C) radial kurtosis [33]. 
 
 
Figure 3: Representative DTI-derived parametric maps from a patient with a grade II astrocytoma. In FA, the white 
matter (WM) appears hyper-intense, while the cerebrospinal fluid (CSF) and the tumour appear hypo-intense. In 
contrast, in MD, AD and  RD, the CSF and the tumour are hyper-intense, while the WM appears hypo-intense.  
 
 
Figure 4: Follow-up MRI of a left frontal primary GBM treated by surgery and stereotactic radiosurgery (SRS). (A) 
axial contrast-enhanced T1-weighted image demonstrating the enhancing tumour in the frontal lobe, (B) The 
relative cerebral blood volume rCBV colorimetric map overlaid on the MR image and (C) pixel-by-pixel Ktrans 
colorimetric map showing heterogenous K
trans
 values from the tumour [60]. 
 
Figure 5: DSC maps showing the tumour (arrow) from a patient with grade II (A) and grade III (B) glioma. The 
CBV and CBF maps in (A) show elevated blood volume and blood flow within the tumour (8.16 mL/100 mL
2
, 111 
ml/100 g, respectively) compared with the normal WM (4.9 mL/100 mL
2
, 71.4 mL/100 g/min, respectively). 
 
Table 1: Summary of diffusion and perfusion imaging parameters, there physiological 
interpretation in tumours and their general trends in high (HGG) versus low grade gliomas 
(LGG).  
 
Parameter Reflect Values in HGG 
[16,37,42,47,54, 74]
 
Values in LGG 
FA Microstructure integrity Higher Lower 
MD Oedema, cellularity and necrosis Lower Higher 
AD Axonal integrity/degeneration Higher Lower 
RD Myelin damage Higher Lower 
rCBV Degree of angiogenesis Higher Lower 
rCBF Degree of blood flow Higher Lower 
K
trans
 Vascular Permeability and blood flow Higher Lower 
rMTT Vascular Permeability. Lower Higher 
 
FA= fractional anisotropy, MD = mean diffusivity, AD = axial diffusivity, RD = radial 
diffusivity, rCBV = relative cerebral blood volume, rCBF = relative cerebral blood flow, K
trans
 = 
rate constant of the contrast agent from vascular to insterstitial compartment, rMTT = relative 
mean transit time of the contrast agent from the vascular to the interstitial compartment. 
Numbers within brackets indicate the references for the source of these findings. 
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